Eris Lifesciences Limited — Important, 25-10-2024: General Updates

Eris Lifesciences' Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024. The company revealed a net profit of ₹28.10 crore for the quarter. Additionally, Eris is set to acquire a 30% stake in Levim Lifetech Private Limited through a cash investment of ₹54 crore, aimed at expanding its biotechnology portfolio. Both the financial results and acquisition details have been disclosed in compliance with regulatory requirements.